Treatment choices for people infected with HCV

Research output: Contribution to journalArticlepeer-review


Hepatitis C virus (HCV) infection is one of the leading causes of liver disease in the world. It is a common cause of cirrhosis and hepatocellular carcinoma (HCC), as well as the most common reason for liver transplantation. Thus, appropriate therapeutic approaches have a strong clinical impact on the morbidity and mortality of HCV-infected patients. In this review we outline the most recent results in the therapy of HCV chronic hepatitis. Patients with the best prognostic factors treated with combination therapy (peginterferon and ribavirin) obtained asustained response rate of 80-95%. We also provide some hints on the most promising results of the newest therapeutic options, which include molecules that inhibit specific enzymes, such as inhibitors of serine proteases, which are now in preclinical or early phase human trials. Host factors influencing the rate of response are also outlined.

Original languageEnglish
Pages (from-to)708-712
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number5
Publication statusPublished - May 2004


  • Anti-serine
  • Chronic hepatitis C
  • Hepatitis C virus
  • Interferon
  • Ribavirin

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology


Dive into the research topics of 'Treatment choices for people infected with HCV'. Together they form a unique fingerprint.

Cite this